Three-dimensional solid polymeric foams and a microfluidic process to design them

Patent metadata

Field	Value
Publication number	US-2021108045-A1
Application number	US-202017066815-A
Country	US
Kind code	A1
Filing date	Oct 9, 2020
Priority date	Oct 11, 2019
Publication date	Apr 15, 2021
Grant date	—

Abstract

Organic solid three-dimensional polymeric foams, a process for preparing the same, and use thereof, the foams includes a solid continuous phase and pores, wherein the foams have a pore size ranging from 50 nm to 200 μm and a volumetric fraction of the solid continuous phase is from 0.1 to 60%, with respect to the total volume of the foams, and a polydispersity index from 1 to 30%, the foams being ordered over a volume of at least 100 pores.

First claim

1 . An organic solid three-dimensional polymeric foam consisting of, or comprising, a solid continuous phase and pores,
wherein said solid continues phase is a cross-linked organic polymer, wherein said pores are separated by plateau borders, the meeting points of said plateau borders forming nodes, wherein said foam has:
a pore size comprised from 50 nm to 200 μm, or from 50 nm to less than 10 μm, or from 10 to 200 μm,
a volumetric fraction of the solid continuous phase comprised from 0.1 to 60%, with respect to the total volume of the foam,
a flexibility/elasticity comprised from 10 to 10 7 Pa,
a polydispersity index comprised from 1 to 30%,
wherein said solid three-dimensional polymeric foam is ordered over a volume of at least 100 pores, or over a volume of 100 to 1000 pores, or 1000 pores.

2 . The organic solid three-dimensional polymeric foam according to claim 1 , wherein the organic polymer is chosen from the groups of:
biopolymers, or polysaccharides, polyvinyl alcohols polylactic acids (PLA), Poly-L-Lactic acids (PLLA), poly(lactic-co-glycolic acids) (PLGA), polyethylene glycols (PEG), polyacrylates (PA), polymethacrylates (PMA), Poly(methyl methacrylates) (PMMA), polystyrenes (PS), poly-N-vinylpyrrolidones (PVP), Polyethyleneglycol acrylates (PEGA), polyethyleneglycol methacrylates (PEGMA), polyethyleneglycol diacrylates (PEGDA), polyethyleneglycol dimethacrylates (PEGDMA), or mixtures of said organic polymers, said organic polymer being cross-linked with a cross-linker chosen from the group of: glycerol-phosphate disodium salt, glyoxal, genipin, sodium tripolyphosphate (TPP), divinyl sulfone (DVS), calcium chloride (CaCl 2 ), calcium acetate, glutaraldehyde, polyaldehydes and butanediol glycidyl ether, or mixtures of said cross-linking agents.

3 . The organic solid three-dimensional polymeric foam according to claim 1 , wherein the organic polymer is a polysaccharide of natural origin, chosen from the group consisting of chitosan, hyaluronic acid, alginate, starch, dextrin, glycogen, dextran, gellan, pullulan, cellulose, hemicellulose, pectin, curdlan, agar-agar, alginate, carrageenan, chitosan, hyaluronic acid, xanthan, zooglan and succinoglycan,
or mixtures of said organic polymers, said organic polymer being cross-linked with a cross-linker chosen from the group of: glycerol-phosphate disodium salt, glyoxal, genipin, sodium tripolyphosphate (TPP), divinyl sulfone (DVS), calcium chloride (CaCl 2 ), calcium acetate, glutaraldehyde, polyaldehydes and butanediol glycidyl ether, or mixtures of said cross-linking agents.

4 . The organic solid three-dimensional polymeric foam according to claim 1 , wherein the organic polymer is chitosan, cross-linked with glyoxal.

5 . The organic solid three-dimensional polymeric foam according to claim 1 , wherein the pores are comprised of from 1 to 10 population(s) of pores, or of from 2 to 10 population(s) of pores, or 1 or 2 populations of pores, each population of pores having a specific pore size and/or a specific polydispersity index,
said pore size being comprised from 50 nm to 200 μm, or from 50 nm to less than 10 μm, or from 10 to 200 μm, and polydispersity index being comprised from 1 to 30%.

6 . The organic solid three-dimensional polymeric foam according to claim 1 ,
wherein the organic solid three-dimensional polymeric foam has an open pore structure, or a partially open pore structure, said partially open pore structure comprising both open and closed pores, wherein less than 100%, but more than 0% of the pores are open pores, compared to the sum of open and closed pores, or wherein the organic solid three-dimensional polymeric foam has a closed pore structure.

7 . The organic solid three-dimensional polymeric foam according to claim 1 , wherein the solid continuous phase has:
a crystalline body cubic centered (BCC) structure, said foam having a volumetric fraction of the solid continuous phase comprised from 5 to 7% compared to the total volume of the foam, or both a crystalline body cubic centered (BCC) structure and a crystalline face cubic centered (FCC) structure, said foam having a volumetric fraction of the solid continuous phase comprised from more than 7 and 10% compared to the total volume of the foam, or a crystalline face cubic centered (FCC) structure, said foam having a volumetric fraction of the solid continuous phase comprised from more than 10 to 25% compared to the total volume of the foam, or a crystalline Weaire-Phelan structure, said foam having a volumetric fraction of the solid continuous phase comprised from 5 to 7% compared to the total volume of the foam, said solid three-dimensional polymeric foam being ordered.

8 . The organic solid three-dimensional polymeric foam according to claim 1 , wherein the organic solid three-dimensional polymeric foam further comprises:
nanoparticles, or an active pharmaceutical ingredient, or a contrast agent, or a dye, said active pharmaceutical ingredient optionally comprising a radiotracer, said nanoparticles, active pharmaceutical ingredient, contrast agent or dye being optionally coupled to a fluorophore.

9 . The organic solid three-dimensional polymeric foam according to claim 1 , wherein the organic solid three-dimensional polymeric foam further comprises:
nanoparticles, or an active pharmaceutical ingredient, or a contrast agent, or a dye, said nanoparticles, active pharmaceutical ingredient, contrast agent or dye being optionally coupled to a fluorophore, said active pharmaceutical ingredient optionally comprising a radiotracer, wherein said nanoparticles, active pharmaceutical ingredient, contrast agent or dye are located within the three-dimensional structure of the solid foam, or within the plateau borders and the nodes of the solid foam.

10 . The organic solid three-dimensional polymeric foam according to claim 1 , wherein the organic solid three-dimensional polymeric foam further comprises:
nanoparticles, chosen from the group of:
metal oxide nanoparticles, or titanium dioxide (TiO 2 ) or aluminum oxide (Al 2 O 3 ) nanoparticles,
metallic nanoparticles, or silver (Ag), gold (Au), iron (Fe), nickel (Ni), copper (Cu) or germanium (Ge) nanoparticles,
bi-metallic nanoparticles, or gallium arsenide (GaAs), lead telluride (PbTe), or iron platinum (FePt) nanoparticles,
tri-metallic nanoparticles, or aluminum gallium arsenide (Al x Ga 1-x As) nanoparticles,
ceramic nanoparticles, or silicon carbide (SiC) or tungsten carbide (WC) nanoparticles,
magnetic nanoparticles, or iron oxide (Fe 2 O 3 ) nanoparticles,
silica (SiO 2 ) nanoparticles,
polymeric nanoparticles,
or mixtures thereof, or an active pharmaceutical ingredient, chosen from the group of:
anti-inflammatory drugs, or diclofenac, ibuprofen, acetyl salicylic acid, or steroid based anti-inflammatory drugs,
anti-cancer drugs, or paclitaxel, docetaxel, or doxorubicin,
analgesics, or morphine,
antibiotics, or penicillin or sulfonamide antibiotics,
said active pharmaceutical ingredient optionally comprising a radiotracer, or a contrast agent or ipodate sodium, or a dye, or an organic dye, or a water soluble organic dye, pigments, or quantum dots, or a dye chosen from the group consisting of: Fluorescein, Eosin, Amaranth, Sanolin Blue NBL, Anthocyanins, methylene blue, indocyanine green (ICG), Rhodamine B, Cyanine, Evans Blue, Primulin, Isamine Blue, and Naphtol green B, said nanoparticles, active pharmaceutical ingredient, contrast agent or dye being optionally coupled to a fluorophore.

11 . A process of preparation of an organic solid three-dimensional polymeric foam consisting of, or comprising, a solid continuous ph

Assignees

• Paris Sciences Lettres Quartier Latin
• Centre Nat Rech Scient
• Ecole Superieure Physique & Chimie Ind Ville De Paris

Inventors

• Maimouni Ilham
• Russo Maria
• Cossy Janine
• Tabeling Patrick

Classifications

• C08J2207/10

  Medical applications, e.g. biocompatible scaffolds · CPC title

• C08J3/24

  Crosslinking, e.g. vulcanising, of macromolecules (mechanical aspects B29C35/00; crosslinking agents C08K) · CPC title

• C08J2305/08

  Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof · CPC title

• C08J2205/042

  Nanopores, i.e. the average diameter being smaller than 0,1 micrometer · CPC title

• C08J2205/044

  Micropores, i.e. average diameter being between 0,1 micrometer and 0,1 millimeter · CPC title